Tempus

A DNA panel assay developed by Tempus that has been successfully brought through the regulatory process for companion diagnostics.

523 gene liquid biopsy panel (114 gene enhanced region) for solid tumors. Clinical sequencing performed to >5000x and >1500x unique coverage for enhanced and additional regions, respectively. Measures changes in ctDNA tumor fraction to determine early response to immunotherapy for advanced cancers.

NGS-based in vitro diagnostic test for the detection of BRAF and RET rearrangements in FFPE tumor tissue specimens from patients with solid malignant neoplasms.

A whole-transcriptome RNA sequencing assay by Tempus that identifies patients similarly to IHC but provides more granular stratification for patient outcomes.

Whole transcriptome RNA sequencing test included in Comprehensive Therapy Selection orders for solid tumors.

Comprehensive assessment of DNA (648 genes) and RNA whole transcriptome sequencing for hematologic malignancies, offering validated fusion detection, prognostic and/or diagnostic considerations, and therapeutic matching.

DNA test included in Comprehensive Therapy Selection orders for hematologic malignancies.

A comprehensive immunotherapy platform that provides actionable and cutting-edge services for life sciences partners advancing IO therapies, including antibody-drug conjugates (ADCs), TCR therapies, and immune checkpoint inhibitors (ICIs).

A monitoring approach using ctDNA to assess treatment response to immunotherapy, helping guide treatment decisions and predict outcomes.

A laboratory developed test to predict the probability of a patient’s cancer having homologous recombination deficiency (HRD) phenotype, using DNA genome-wide loss of heterozygosity or RNA expression data.

An algorithmic test requiring RNA sequencing for processing, ordered as an add-on to DNA and RNA sequencing combinations.

Uses tumor RNA expression results to predict the patient’s most likely cancer type(s) from 68 possible cancer types, intended for cancers of unknown primary and difficult diagnostic cases.

An algorithmic test to refine diagnosis for cancers with uncertain origin, ordered as an add-on to DNA and RNA sequencing combinations.

Spatial transcriptomics platform mapping gene expression of cells in their native tissue environment at 25K read pairs per tissue-covered spot.

Spatial transcriptomics platform offering 275M read pairs for fully captured area gene expression mapping.

Spatial transcriptomics platform mapping gene expression of cells in their native tissue environment at 25K read pairs per tissue-covered spot.

Proteomics platform measuring approximately 11,000 protein targets with representation of over 200 biological pathways including oncology, neurology, inflammation, and cardiology.

Proteomics platform assessing approximately 6,000 protein targets representing over 200 biological pathways including oncology, neurology, inflammation, and cardiology.

Single-cell RNA sequencing product with optional TCR / BCR readouts for high-resolution cellular diversity and gene expression analysis.

Single-cell RNA sequencing product for gene expression analysis.

Single-cell RNA sequencing product combining ATACseq and gene expression (GEX) for multi-omic analysis.

Single-cell RNA sequencing product with optional TCR / BCR readouts for high-resolution cellular diversity and gene expression analysis.

Proteomics platform quantifying approximately 5,400 protein targets with eight target 384-plex panels for disease-specific and biological process research.

Proteomics platform measuring approximately 2,400 protein targets for advanced biomarker discovery and multi-omic analysis.

Highlights areas most likely to harbor cancer and in situ neoplasms in breast tissue, focusing review on critical regions of the slide.

Identifies mitotic hotspots and provides a count and density of mitotic instances to aid in grading breast cancer.

Categorizes areas suspicious for cancer by Gleason pattern, providing predictions for primary and secondary Gleason grades, and offers percentage and linear measurements of tumor burden.

Aids in the detection of suspicious foci around nerve fibers to identify the presence of perineural invasion in prostate cancer.

FISH testing for 1p/19q co-deletion, a diagnostic marker for oligodendrogliomas with prognostic and predictive value.

Immunohistochemistry testing using four PD-L1 clones (22C3, 28-8, SP142, SP263) tailored to patient cancer type, with automatic clone selection based on ICD-10 codes.

Detects folate receptor alpha (FRα) protein expression, commonly overexpressed in ovarian and certain gynecological cancers.

Evaluates deficiencies in mismatch repair proteins to identify loss of MMR pathway function.

Detects Claudin-18 (CLDN18) protein expression, often elevated in gastric and gastroesophageal adenocarcinomas.

648 gene panel, tumor/normal matched for solid tumors, and two companion diagnostic (CDx) claims for colorectal cancer (CRC) patients.

A next generation sequencing-based in vitro diagnostic device for detecting single nucleotide variants (SNVs) and insertion and deletion alterations (INDELs) in 648 genes from FFPE tumor tissue specimens of cancer patients.

A comprehensive FDA-approved sequencing panel covering 648 genes for solid tumor and normal DNA analysis.

The Tempus ECG-AF algorithm analyzes recordings of 12-lead electrocardiogram (ECG) devices to detect signs associated with a patient experiencing atrial fibrillation (AF) within the next 12 months. It is intended for use on resting 12-lead ECG recordings collected at healthcare facilities from patients 65 years or older without a known history of AF or other specified conditions.

A comprehensive genomic profiling panel analyzing 648 genes from tumor and normal specimens to identify clinically relevant somatic alterations, incidental germline findings, and immunotherapy markers to inform patient care.

The Tempus ECG-Low EF algorithm analyzes ECG data to provide a binary output indicating potential low left ventricular ejection fraction (LVEF ≤40%). It is not a stand-alone diagnostic tool and should be used alongside other clinical information. Not intended for patient monitoring or use on ECGs with paced rhythms.

The non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of patients with advanced solid tumors, identifying mutations in 105 genes including SNVs, INDELs, CNGs, and gene rearrangements. It provides clinical decision support with therapy options and clinical trials matched to the patient’s genomic profile, reporting Microsatellite Instability High (MSI-H) and Blood Tumor Mutational Burden (bTMB) status when detected.

A ctDNA seq panel that interrogates 523 genes focused on oncogenic and resistance mutations in cell-free DNA (cfDNA) to help clinicians identify treatment opportunities. Identifies SNV, insertions / deletions, CNVs, gene rearrangements from select genes, as well as MSI and bTMB. Measures changes in ctDNA tumor fraction to determine early response to immunotherapy for patients with advanced cancers.

An AI-powered ECG analysis platform developed with Geisinger that analyzes 12-lead ECG data to predict mortality risk and identify patients at high risk for AFib-related stroke, even when ECGs appear normal.

A clinical whole exome sequencing panel for comprehensive DNA analysis in oncology.

xM (NeXT Personal® Dx) is an ultra-sensitive, tumor-informed whole genome assay for solid tumors that detects molecular markers at very low concentrations to monitor residual disease, recurrence, and immune-oncology treatment response.

A ctDNA seq panel that detects oncogenic drivers and resistance mutations, assesses for MSI, and identifies SNVs, INDELs, and CNVs. Measures changes in ctDNA tumor fraction to determine early response to immunotherapy for patients with advanced cancers.

xE is a whole exome 19,000+ gene panel by DNA sequencing that provides potentially actionable and biologically relevant alterations, TMB, as well as potential germline findings.

A comprehensive WGS assay optimized for clinically relevant alterations in Acute Myeloid Leukemia (AML), Chronic myelogenous leukemia (CML), Myeloproliferative neoplasm (MPN), and Myelodysplastic Syndromes (MDS). It characterizes recurrent structural variants, extensive copy number alterations, and single nucleotide variants/indels with high concordance to targeted DNA, RNA sequencing, and cytogenetic profiling.

78-gene germline panel that includes genes associated with hereditary breast, ovarian, pancreatic, prostate, colorectal, endometrial, gastric, small bowel, urothelial, renal, plus an array of additional cancers.

Lens is the agentic platform for oncology drug development, built on the world's largest real-world multimodal dataset and proven to increase probability of technical success. It brings state-of-the-art GPU/CPU infrastructure directly to a library of 9M+ records to surface breakthroughs faster, all from a single, AI-first platform.

A streamlined ordering solution that includes a suite of tests tailored to a patient's cancer type, covering DNA, RNA, and biomarker tests for solid tumors and hematologic malignancies.

Solid tumor testing when a matched normal specimen is unavailable or cannot be sequenced successfully.

Targeted panel of approximately 52 hereditary cancer genes with an average coverage of 500x.

A sequencing panel for whole-transcriptome RNA analysis to identify clinically actionable fusions and gene expression.

AI-enabled pathology algorithm with FDA Breakthrough Device Designation for breast lymph node analysis.

An RNA sequencing assay cleared by 510(k) for detecting RET and BRAF rearrangements, used as a companion diagnostic tool.

Full Illumina NGS suite of instruments offered by Tempus for faster, powerful whole genome sequencing (30x-200x), low pass WGS with or without imputation, and single-cell whole transcriptome sequencing with flexible coverage.

A tumor-naïve minimal residual disease (MRD) ctDNA assay that integrates methylation and genomic variant data to deliver a binary MRD call blinded to clinical outcomes, used for postsurgical ctDNA detection in colorectal cancer patients.

Optional add-on for CancerNext® or CancerNext-Expanded® that analyzes RNA to support the classification and detection of DNA variants.

A care pathway intelligence platform that uses AI to support clinicians in closing care gaps by identifying patients who have not received treatment consistent with applicable guidelines and delivering customized notifications within clinical workflows.

Tailored testing add-ons including homologous recombination deficiency (HRD), pharmacogenomic markers (UGT1A1, DPYD), immune profiling score (IPS), tumor origin (TO), and PurIST® classifier.

Additional tailored testing markers including mismatch repair (MMR), CLDN18, PD-L1, HER2, FOLR1, MGMT, C-MET, and 1p/19q chromosomal alterations.

An optional RNA sequencing add-on to hereditary cancer panels to enhance genetic insights.

A connected suite of AI applications to help institutions advance patient care by identifying and closing gaps in care, accelerating clinical trial enrollment, and providing on-demand patient insights.

A laboratory developed test using an RNA-based algorithm to classify pancreatic ductal adenocarcinomas (PDAC) into basal-like or classical subtypes to inform first-line chemotherapy selection.

AI-powered solution to analyze and quantify cardiac MR images, providing advanced viewing and automated reporting to improve efficiency and accuracy in flow visualization, functional analysis, and tissue characterization.

ctDNA Tumor Fraction assay for ctDNA quantification and monitoring. Measures changes in ctDNA tumor fraction to determine early response to immunotherapy for patients with advanced cancers. Available for research use only.

A testing approach tailored to a patient’s unique tumor profile, offering high specificity and sensitivity for long-term surveillance and monitoring after checkpoint inhibitor therapy.

AI application predicting the status of approximately 1,600 biomarkers across 505 genes from a single H&E slide to accelerate biomarker screening and sample selection for testing across NGS, hotspot testing, IHC, and special stains.

A guideline-based, disease-specific test option that includes 13 genes associated with hereditary breast cancer, where screening, treatment, and/or surgical intervention may be indicated.

A multimodal biomarker used as a prognostic indicator for adult patients with metastatic and/or stage IV pan-solid tumor disease who are candidates for immune checkpoint inhibitor (ICI) based therapy.

Single-cell RNA sequencing product offering up to 10K cells and 1-12 samples for high-resolution cellular diversity analysis and gene expression assessment.

A germline DNA test that clinically reports 13 genes with known roles in pharmacokinetics, pharmacodynamics, and immune response to certain FDA approved medications. It includes genotyping for SNVs, indels, and CNVs in CYP2D6, validated for use with genomic DNA from saliva or buccal swabs.

A broader genetic testing panel for hereditary cancer risk, powered by Ambry Genetics®.

Test for MGMT promoter methylation, a prognostic and predictive biomarker for glioma response to alkylating agents.

Designed to help identify patients at elevated risk for toxicity and serious adverse effects from 5-FU and capecitabine treatments, especially in colorectal, breast, pancreatic, and other GI cancers.

A genetic testing panel for assessing hereditary cancer risk, powered by Ambry Genetics®.

A pharmacogenomic testing panel to guide medication selection and dosing for personalized treatment.

Identifies patients at elevated risk for toxicity from treatment with irinotecan, sacituzumab govitecan, and/or belinostat by detecting genetic polymorphisms in the UGT1A1 gene.

A focused genetic panel for hereditary breast cancer risk assessment, powered by Ambry Genetics®.

Methylation testing assay providing data for methylation profiling, biological age calculations, and EWAS analysis with an optimized workflow for high-quality data.

A suite of cloud-hosted viewer and applications with nine FDA clearances for pathology image analysis.

A pathology image viewer compatible with three major whole slide image scanners, cleared by FDA 510(k).

An AI-powered clinical notetaker for psychiatry that automates patient notes with precision, saving clinicians time.

Immunohistochemistry testing for c-Met expression, available as an add-on test.

Immunohistochemistry testing for HER2 with reflex to ERBB2 FISH for equivocal results, including additional analysis for HER2-ultralow breast cancer assessment.

Advanced viewing and automated reporting software for cardiac MR images to improve efficiency and accuracy in flow visualization, functional analysis, and tissue characterization.

A software platform that tracks adverse drug reactions and patient response to selected treatments as part of the Tempus Mental Health Platform.